2013
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
Hamid O, Sosman J, Lawrence D, Sullivan R, Ibrahim N, Kluger H, Boasberg P, Flaherty K, Hwu P, Ballinger M, Mokatrin A, Kowanetz M, Chen D, Hodi F. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). Journal Of Clinical Oncology 2013, 31: 9010-9010. DOI: 10.1200/jco.2013.31.15_suppl.9010.Peer-Reviewed Original ResearchObjective response rateMM ptsPD-L1Tumor shrinkageAntitumor activityImmunotherapy-responsive diseasePD-L1 overexpressionTreatment-related deathsPD-L1 statusPD-L1 antibodiesHuman monoclonal antibodyInitial antitumor activityPt ageRECIST responseRECIST v1.1Median durationPrior surgeryPS 0Radiographic progressionSystemic therapyElevated ASTPD-1Dose escalationHistologic subtypeInitial treatmentVascularity of primary and metastatic renal cell carcinoma specimens
Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens. Journal Of Translational Medicine 2013, 11: 15. PMID: 23316728, PMCID: PMC3561185, DOI: 10.1186/1479-5876-11-15.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaMicrovessel areaMetastatic samplesCell carcinomaMetastatic sitesPrimary tumorMetastatic renal cell carcinomaRenal cell carcinoma tumorsClear cell tumorsClear cell carcinomaPredictive biomarker studiesAnti-angiogenic drugsAnti-angiogenic therapyTypes of tumorsHigh response ratePrimary nephrectomyHistologic subtypeCell tumorsDifferent histologyPapillary histologyCD 34Variable histologyClinical studiesClear cellsTumor vascularity
2012
CD70 expression patterns in renal cell carcinoma
Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL. CD70 expression patterns in renal cell carcinoma. Human Pathology 2012, 43: 1394-1399. PMID: 22401771, PMCID: PMC3374042, DOI: 10.1016/j.humpath.2011.10.014.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaCD70 expressionPapillary tumorsHigh CD70 expressionExpression of CD70Clear cell tumorsNovel therapeutic agentsRenal cell carcinoma specimensPathologic variablesHistologic subtypePrognostic valueCell subsetsCell tumorsUnivariate analysisClinical trialsImmune escapeSitu protein expressionT lymphocytesClear cellsTissue microarrayCarcinoma specimensCD70Immunohistochemistry-based methodMultivariate analysis